- Home
- XGN vs ABOS Comparison
XGN vs ABOS Comparison
Compare XGN & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XGN | ABOS |
|---|---|---|
| Founded | 2002 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.5M | 155.7M |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | XGN | ABOS |
|---|---|---|
| Price | $3.26 | $3.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | ★ $11.00 | $7.50 |
| AVG Volume (30 Days) | ★ 341.3K | 324.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.06 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $20.99 | N/A |
| Revenue Next Year | $11.27 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.80 | $0.86 |
| 52 Week High | $12.23 | $3.41 |
Technical Indicators
Market Signals| Indicator | XGN | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 35.45 | 72.70 |
| Support Level | $3.15 | $1.21 |
| Resistance Level | $4.00 | N/A |
| Average True Range (ATR) | 0.30 | 0.24 |
| MACD | 0.06 | 0.05 |
| Stochastic Oscillator | 25.51 | 91.35 |
Price Performance
Historical ComparisonAbout XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.